Linda Cathavina Bain
Independent Non-Executive DirectorMs. Linda Cathavina Bain, CPA, is Independent Director at Remix Therapeutics, Inc from April 2025. She serves as a venture partner at Atlas Venture, a venture capital firm focused on biotechnology, since April 2025. She served as Chief Operating Officer & Chief Financial Officer of Mariana Oncology, Inc. since May 2023 until April 2025. She has been an Independent Director at Hemab Therapeutics Holdings, Inc. since January 2022. She was Member of Scientific Advisory Board at Remix Therapeutics Inc. since June 2023. She served as Director at VBI Vaccines Inc. since July 2021 until September 09, 2022. She has been Independent Director at Arvinas, Inc. since June 11, 2020. She has been Non-Executive Director at Autolus Therapeutics Plc since June 15, 2018. Ms. Bain served as the Chief Financial Officer at Codiak Biosciences, Inc. since December 2015 and serves as its Treasurer. Prior to joining Codiak, Ms. Bain served as the Chief Financial Officer and Treasurer of Adverum Biotechnologies, Inc (Formally known as Avalanche Biotechnologies, Inc.) from April 2014 to November 17, 2015 and served as its Principal Financial & Accounting Officer. Ms. Bain served as Vice President of Finance and Business Operations at bluebird bio, Inc. from October 2011 to March 7, 2014 and Chief Accounting Officer and Treasurer from June 2013 to March 7, 2014. Ms. Bain served as Principal Accounting Officer at bluebird bio, Inc. since March 2013 until March 7, 2014. She joined bluebird bio in October 2011. She has extensive finance and audit experience, including few years as a Strategic Business Partner in the pharmaceutical and biotech industry. She served as Vice President of Finance at Genzyme Corporation from September 2008 to September 2011, where she played a key role in selling Genzyme Genetics to LabCorp. At Genzyme, she led the global manufacturing and operations finance team. She held senior roles at Genzyme Corporation and was Vice President of Global Manufacturing and Operations and Vice President of Finance, Genzyme Genetics. From September 2007 to September 2008, she served as Vice President at Fidelity Investments and from May 2000 to September 2007, she held several positions at AstraZeneca plc. She served as an Audit Manager at Deloitte & Touche. She is a Certified Public Accountant and a Chartered Accountant (SA). She is Director at Hemab ApS since January 2022. Ms. Bain is an accomplished financial and business executive with finance, strategy and Board experience in both small and large public companies in the biotechnology and pharmaceutical industry. Ms. Bain has an Honors B.A from the University of the Orange Free State, South Africa. Ms. Bain received her B.S. in Accounting and Business Administration and Honors Degree in Accounting and Business Administration from the University of the Free State in South Africa.
公司職務
- 公司名稱Autolus Therapeutics plc股票代碼AUTL職務Independent Non-Executive Director共事同僚
- CMChristian Martin ItinCEO & Director
- MWMichael Weston BonneyIndependent Chairman of the Board
- MPMartin PuleFounder, Senior VP & Chief Scientific Officer
- RFRobert F. DolskiSenior VP & CFO
- CVChristopher VannSenior VP & COO
- PMPatrick McIlvennySenior VP of Finance, Chief Accounting Officer & Principal Accounting Officer
- CMCynthia Marie ButittaIndependent Non-Executive Director
- WDWilliam Douglas YoungIndependent Non-Executive Director
- 公司名稱Hemab Therapeutics Holdings, Inc.股票代碼COAG職務Independent Director共事同僚
- BSBenny SorensenPresident, CEO & Director
- JMJohn Michael MaraganoreIndependent Chairman
- MNMads Nikolaj Behrndt-EriksenCFO & GM
- CECatherine Eilleen MadiganChief Medical Officer
- ASAnanthram Sreenivasa MurthyChief Operating Officer
- KWKaren WeisbachChief People & Culture Officer
- LCLinda Cathavina BainIndependent Director
- AKAkshay Krishnadas VaishnawIndependent Director
- KWKeli WalbertDirector
